{"nctId":"NCT00168389","briefTitle":"A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema","startDateStruct":{"date":"2005-02"},"conditions":["Diabetic Macular Edema"],"count":494,"armGroups":[{"label":"Dexamethasone 700 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Dexamethasone"]},{"label":"Dexamethasone 350 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Dexamethasone"]},{"label":"Sham","type":"SHAM_COMPARATOR","interventionNames":["Other: Sham"]}],"interventions":[{"name":"Dexamethasone","otherNames":["Posurdex®","Ozurdex®"]},{"name":"Sham","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* 18 years of age or older with diabetic macular edema;\n* Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or worse);\n* Visual acuity in other eye no worse than 20/200\n\nKey Exclusion Criteria:\n\n* Known anticipated need for ocular surgery within first 12 months of study;\n* History of glaucoma or current high eye pressure requiring more than 1 medication;\n* Uncontrolled systemic disease;\n* Known steroid-responder;\n* Use of systemic steroids\n* Use of Warfarin/Heparin","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye","description":"BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":null},{"groupId":"OG001","value":"18.7","spread":null},{"groupId":"OG002","value":"13.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline in BCVA in the Study Eye","description":"BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The average BCVA is calculated across study visits for each patient. A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":"10.5"},{"groupId":"OG001","value":"55.9","spread":"9.64"},{"groupId":"OG002","value":"56.8","spread":"8.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"8.26"},{"groupId":"OG001","value":"4.3","spread":"8.49"},{"groupId":"OG002","value":"1.9","spread":"7.74"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in BCVA in the Study Eye","description":"BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":"10.5"},{"groupId":"OG001","value":"55.9","spread":"9.64"},{"groupId":"OG002","value":"56.8","spread":"8.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"13.89"},{"groupId":"OG001","value":"5.0","spread":"11.97"},{"groupId":"OG002","value":"0.8","spread":"11.89"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With a BCVA Improvement of ≥10 Letters From Baseline in the Study Eye","description":"BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7","spread":null},{"groupId":"OG001","value":"34.3","spread":null},{"groupId":"OG002","value":"23.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline in Retinal Thickness as Measured by Optical Coherence Tomography (OCT)","description":"OCT is a laser-based, noninvasive, diagnostic system that provides high-resolution, three-dimensional images of the retina from which retinal thickness can be measured. The average OCT retinal thickness is calculated across study visits for each patient. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"436.7","spread":"145.88"},{"groupId":"OG001","value":"457.4","spread":"158.09"},{"groupId":"OG002","value":"468.7","spread":"129.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-101.1","spread":"119.17"},{"groupId":"OG001","value":"-103.9","spread":"137.88"},{"groupId":"OG002","value":"-37.8","spread":"103.96"}]}]}]},{"type":"SECONDARY","title":"10th Percentile for Time to BCVA Improvement of ≥15 Letters From Baseline in the Study Eye","description":"BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). Shorter durations of time to improvement are best. The 10th percentile represents the first 10% of patients to reach a BCVA improvement of ≥15 letters from baseline in the study eye.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"150","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With BCVA Improvement of ≥15 Letters From Baseline in the Study Eye at 3-month Intervals","description":"BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"13.9","spread":null},{"groupId":"OG002","value":"6.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"10.2","spread":null},{"groupId":"OG002","value":"7.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"18.1","spread":null},{"groupId":"OG002","value":"8.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":null},{"groupId":"OG001","value":"15.1","spread":null},{"groupId":"OG002","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"16.3","spread":null},{"groupId":"OG002","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":null},{"groupId":"OG001","value":"9.6","spread":null},{"groupId":"OG002","value":"10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":null},{"groupId":"OG001","value":"15.1","spread":null},{"groupId":"OG002","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"15.1","spread":null},{"groupId":"OG002","value":"10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":null},{"groupId":"OG001","value":"19.3","spread":null},{"groupId":"OG002","value":"12.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":null},{"groupId":"OG001","value":"19.9","spread":null},{"groupId":"OG002","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":null},{"groupId":"OG001","value":"17.5","spread":null},{"groupId":"OG002","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":null},{"groupId":"OG001","value":"19.9","spread":null},{"groupId":"OG002","value":"12.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":null},{"groupId":"OG001","value":"18.7","spread":null},{"groupId":"OG002","value":"13.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":52,"n":160},"commonTop":["Cataract","Intraocular Pressure Increased","Conjunctival Haemorrhage","Vitreous Haemorrhage","Macular Oedema"]}}}